Drugs / IL-15
IL-15
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02689453 | Jan 2017 → Jun 2021 | T-cell prolymphocytic leukemia, adult T-cell leukemia/lymphoma, peripheral T-cell lymphoma, not otherwise specified, primary cutaneous T-cell lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01385423 | Sep 2011 → Mar 2015 | acute myeloid leukemia, myelodysplastic syndrome | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT00528489 | Oct 2007 → Jan 2010 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01369888 | May 2011 → May 2014 | metastatic melanoma, skin cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02395822 | Oct 2015 → Dec 2016 | acute myeloid leukemia | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL-15 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02395822 ↗ |
| Known as | recombinant human IL-15 | “To evaluate whether IL-15 potentiates ADCC in humans, we conducted a phase 1 single-center study of recombinant human IL-15 and alemtuzumab in patients with CD52-positive...” PMID 35475910 ↗ Feb 2023 |
| Known as | recombinant human interleukin-15 | “Our initial effort with intravenous bolus recombinant human interleukin-15 (rhIL-15) was limited by postinfusional reactions.” PMID 33883258 ↗ Apr 2021 |
| Known as | rhIL-15 | “Forty-two patients received either intravenous (IV) (NCT01385423) or subcutaneous (SC) (NCT02395822) recombinant human IL-15 (rhIL-15) after lymphodepleting chemotherapy and...” PMID 31266741 ↗ Jul 20192“Our initial effort with intravenous bolus recombinant human interleukin-15 (rhIL-15) was limited by postinfusional reactions.” PMID 33883258 ↗ Apr 2021 “Intravenous Recombinant Human IL-15 (rhIL-15)” NCT01385423 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human IL-15” NCT01369888 ↗ |
| Route | Other | “Group 1 will receive an injection of PENNVAX-B combined with 0.8 mg IL-15 in each deltoid or placebo.” NCT00528489 ↗ |